Welcome to the CIBMTR Forms Instruction Manual. The Table of Contents on the left side of the screen is for navigational purposes; if you are on a mobile device you may find the Table on Contents on the top of the page.

General Instructions provides useful general background information for successfully completing forms.

2804/2814: CRID Assignment and Indication provides explanatory text used to generate a CIBMTR Research ID (CRID) and report the indication.

Transplant Essential Data (TED) Manuals provides explanatory text for each question found on the TED forms.

Comprehensive Baseline & Follow-up Forms Manuals provides explanatory text for each question on the Baseline, Follow-up, IDMs, HLA, and Infusion forms.

Comprehensive Disease Specific Manuals provides explanatory text and additional information for disease indications requiring CIBMTR reporting.

Cellular Therapy Manuals provides explanatory text for completing pre-infusion, infusion, and post-infusion forms

Infection & Miscellaneous Manuals provides explanatory text for manuals such as the Hepatitis Serology, VOD / SOS, and Myelofibrosis CMS Study forms.

Appendices provide additional information beyond the scope of the other manuals.

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. In addition to documenting the changes within each manual section, the most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

Date Manual Section Add/Remove/Modify Description
4/19/19 Multiple Myeloma Response Criteria Modify Modified (struck out text has been deleted and red text has been added) the response criteria for Relapse from CR:
Relapse from CR
Requires one or more of the following:
  • Reappearance of serum or urine M-protein by immunofixation or electrophoresis; and/or
  • Development of ≥ 5% plasma cells in the bone marrow; and/or
  • Appearance of any other sign of progression (e.g., new plasmacytoma, lytic bone lesion, hypercalcemia).
    Positive immunofixation alone in a patient previously classified as achieving a complete response should not be considered a relapse.
4/19/19 Waldenstrom’s Macroglobulinemia Response Criteria Add Added (in red below) the following text for the Progressive Disease response criteria:
Progressive disease (PD)
  • ≥ 25% increase in serum monoclonal IgM spike from lowest nadir on serum electrophoresis and/or
  • Progression of clinically significant findings or symptoms (for example, anemia, adenopathy, constitutional symptoms, amyloidosis, etc.) attributed to WM/LPL
4/19/19 2131: ID Post-HCT Modify Updated the engraftment statuses for questions 167 – 172. The engraftment status have been updated (struck out text has been deleted and red text has been added) as follows:
  • Predominantly or completely donor (≥80% donor chimerism)
  • Mixed chimerism (5 – 79 80% donor)
  • Only host cells detected (<5% donor)
4/19/19 Appendix J: Reporting Comorbidities Add Added (in red below) instruction for reporting a cardiac comorbidity:
The presence of one or more of the following:
  • Any history of coronary artery disease (one or more vessels requiring medical treatment, stent, or bypass),
  • Any history of myocardial infarction, or
  • Any history of congestive heart failure , or
  • LVEF ≤ 50% (or a shortening fraction (SF) of < 26% for pediatric cases) on most recent evaluation prior to the start of the preparative regimen
    Also added instruction to the blue not box describing Hepatic and Renal comorbidities to clarify what to report based on laboratory values closest to the start of the preparative regimen.
4/19/19 Appendix D: How to Distinguish Infusion Types Modify Updated the Co-infusion (with HCT) section to reflect updated cellular therapy forms (added text in red below)
When reporting co-infusions, the Cellular Therapy Product form (4003) and Cellular Therapy Infusion form (4006) is are required for all recipients. The HCT Infusion form (2006) will capture information regarding the product intended for engraftment.
4/19/19 Amyloidosis Response Criteria Modify Modified the following sections (removed text is struck out below, added text is in red) of the Amyloidosis Response Criteria:
Partial Response:
  • ≥ 50% reduction in current serum monoclonal protein levels > 0.5 g/dL
  • ≥ 50% reduction in current urine light chain urine m-protein levels > 100 mg/day with a visible peak
  • ≥ 50% reduction in current free light chain levels > 10mg/dL
    Renal Response:
  • ≥ 50% decrease of at least 0.5 g/day (500mg/24hr) in 24-hour urine protein of > 0.5 g/day (500mg/24hr) pre-treatment and
  • Creatinine clearance or serum creatinine must not have worsened by ≥ 25% over baseline
    If only serum creatinine is obtained, an estimated creatinine clearance can be calculated using the following formula:
    Estimated Creatinine Clearance = [(140 – Age (years)) * Weight (kg)] / [72 * Serum Creatinine (mg/dL)]
    The calculation should be multiplied by 0.85 for women.
4/19/19 2450: Post-TED Modify Provided additional instruction and examples for reporting the current disease status in Questions 237-238.
4/11/19 2450: Post-TED Modify Updated the instruction on how to report Dexamethasone if given for disease relapse or progression post-HCT. Dexamethasone should be reported as “Other Systemic Therapy,” not “Other Therapy.”
3/19/19 2450: Post-TED Add Added the following red warning box instruction (in red below) below question 75 to clarify when to use the CCR option in the Disease Assessment at the Time of Best Response to HCT section of the Post-TED (2450) form:
Continued Complete Remission (CCR) should be reported for all patients who were already in CR at the start of the preparative regimen.


Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.

Post your comment on this topic.

Please do not use this for support questions.
For customer support, please contact us here.

Post Comment